Mizuho Maintains Buy on Revance Therapeutics, Raises Price Target to $35
Portfolio Pulse from jenniferd'souza@benzinga.com
Mizuho analyst Vamil Divan maintains a Buy rating on Revance Therapeutics (NASDAQ:RVNC) and raises the price target from $33 to $35.
June 07, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Vamil Divan maintains a Buy rating on Revance Therapeutics and raises the price target from $33 to $35.
The news of Mizuho maintaining a Buy rating and raising the price target for Revance Therapeutics (RVNC) from $33 to $35 is positive for the stock. This indicates that the analyst has confidence in the company's performance and growth potential, which could lead to an increase in investor interest and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100